Insmed Incorporated (NASDAQ:INSM) COO Sells $3,378,264.75 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 42,975 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the completion of the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Thursday, February 6th, Roger Adsett sold 45,605 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $3,689,444.50.
• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

Shares of INSM traded up $0.64 during mid-day trading on Friday, reaching $79.31. The company had a trading volume of 1,167,289 shares, compared to its average volume of 1,950,375. The company's 50 day simple moving average is $73.38 and its 200 day simple moving average is $73.28. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $82.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $14.19 billion, a price-to-earnings ratio of -14.29 and a beta of 1.11.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently made changes to their positions in INSM. Truist Financial Corp acquired a new stake in shares of Insmed in the 2nd quarter valued at approximately $413,000. GAMMA Investing LLC boosted its position in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 224 shares during the period. Exchange Traded Concepts LLC boosted its position in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 627 shares during the period. Creative Planning boosted its position in Insmed by 31.2% during the 3rd quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company's stock worth $3,279,000 after buying an additional 10,668 shares during the period. Finally, V Square Quantitative Management LLC acquired a new stake in Insmed during the 3rd quarter worth approximately $30,000.

Wall Street Analyst Weigh In

A number of research firms recently commented on INSM. Truist Financial reaffirmed a "buy" rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. raised their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus raised their price target on shares of Insmed from $88.00 to $97.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average price target of $88.71.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.